Abstract:

Objective To investigate the expression of latexin（LXN） in gastric cancer and determine the relationship of its expression with clinical features and prognosis. Methods The expression level of LXN was detected by tissue microarray technology and immunohistochemistry in 143 cases of gastric cancer and paired adjacent normal tissues. The relationship between the expression of LXN and clinical parameters were analyzed as well as overall survival（OS）. Results The positive rate of LXN in gastric cancer tissues was 60.1％（86/143）， lower than 100.0％（143/143） of para-carcinoma tissues（P＜0.05）. A significant correlation was observed between the expression of LXN and N stage（P=0.005）， tumor differentiation（P=0.023）， but not with age， gender， tumor size， T stage and TNM stage. The medium OS of 143 patients was 56.0 months，and for the patients with LXN negative expression was 27.0 months， shorter than 79.5 months of LXN positive expression（P＜0.05）. Multivariate analysis revealed that tumor size was the independent prognostic factor in gastric cancer patients（P=0.018）. Conclusion LXN is down-regulated in gastric cancer and may relate to tumorgenesis and development. Loss of LXN expression is associated with the poor prognosis of gastric cancer.